Background
In 1897, Quinke described a clinical entity that he called meningitis serosa, the clinical features of which were related to increased ICP, possibly from excessive cerebrospinal fluid (CSF) production. Two of his 10 patients could have been diagnosed as having IIH according to our current understanding of the disease. In 1904, Nonne introduced the term pseudotumor cerebri. He described patients who presented initially with tumorlike features but who, on further exploration, did not have intracranial masses. Over the course of the 20th century, this entity captured the interest of various medical specialties: first otologists, then neurosurgeons, then neurologists, and, finally, ophthalmologists. This condition initially was recognized most often in the setting of middle ear infection, prompting Symonds to introduce the term otitic hydrocephalus in 1931. Neurosurgical interest in this disease subsequently emerged in the scientific literature with reports of cranial decompression by Davidoff and Dyke and by Dandy. In 1955 , Foley introduced the term benign intracranial hypertension. Larger series were described in the neurological literature during the following decades. However, the term "benign" was placed in doubt later, in 1982, when Corbett reported that approximately 50% of patients with IIH had visual loss, some even to the extent of blindness. At that time, the interest in using ophthalmic procedures to prevent visual loss gained popularity. Today, the term idiopathic intracranial hypertension often is preferred to avoid confusion between orbital pseudotumor and pseudotumor cerebri.
Definition
Idiopathic intracranial hypertension is diagnosed by use of the following criteria, known as Dandy's "modified" criteria (Table 1) :
• Signs and symptoms of increased ICP;
• Absence of localizing findings on neurological examination, except for isolated VI th nerve palsy, in an awake and alert patient;
• Absence of deformity, displacement, or obstruction of the ventricular system, and otherwise normal neurodiagnostic studies with no other cause for increased ICP; and
• Increased ICP with no cytological or chemical anomalies on CSF examination.
Epidemiology
Idiopathic intracranial hypertension affects women four to nine times more often than men, with onset typically in the second or third decade of life. As many as 90% of patients are obese. The incidence of this disease is 1 to 1.7 per 100,000 in the general population, and it is 20 times more common in obese women of reproductive age. Familial cases have been reported.
Etiology and Possible Associated Pathology
Cerebral venous obstruction or venous hypertension may result from disorders such as chronic respiratory insufficiency, otitis media with petrosal extension, venous sinus thrombosis, or disorders of hypercoagulability. Injury to the arachnoid granulations may result from head trauma and meningitis leading to IIH. Digre proposed a scale for the associations between various diseases and medications and IIH, depending on the number of Wall's criteria that are fulfilled: proven (four); likely (three); probable (two); possible (one); unlikely (zero); and unsupported (see Table 2 ). * Dr. Krisht has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity.
Table 1. Modified Dandy's Criteria for Increased Intracranial Hypertension
Signs and symptoms of increased intracranial pressure No localizing signs other than Cranial Nerve VI palsy in an otherwise awake and alert individual Increased CSF pressure without chemical or cytological abnormalities Normal to small ventricles and no intracranial mass lesion 
Pathogenesis
Patients are said to have secondary intracranial hypertension when a clear cause can be identified. Although the entity has been recognized for more than a century, the pathophysiology of IIH remains a point of debate. Neural hydrodynamics are related to the interactions among three components: the vascular bed; the CSF space; and the brain parenchyma, within the closed system formed by the skull. These interactions create a complex hydraulic environment characterized by varying pressure levels and differentials, as well as varying volumes and compliance. There is evidence that changes in all three components are involved in the pathogenesis of IIH-brain edema and increased brain water content, increased venous pressure and cerebral blood volume, and decreased CSF absorption have all been demonstrated in patients with IIH. Alterations in the relative interactions and dependence of each of the compartments with one another have been implicated in the pathogenesis of IIH. For example, increased ICP leads to compression of the bridging veins and arachnoid granulations, leading to further venous hypertension and decreased CSF absorption. The question remains as to which compartment is primarily involved. It also is possible that the site of primary pathology may be different for each patient.
Association Between Obesity and Idiopathic Intracranial Hypertension
The association between obesity and IIH deserves special attention. Up to 66% of men with IIH and 90% of women with pseudotumor cerebri are obese. The incidence of IIH in women who are 20% heavier than their ideal body weight is 20 times higher than that in the general population. Two mechanisms have been invoked to explain this association: one is mechanical; the second is hormonal. In the mechanical theory, obesity is thought to lead to increased abdominal pressure, increased central venous pressure, and decreased central nervous system venous return. This may lead to venous hypertension, brain edema, decreased CSF absorption, and ultimately, increased ICP. The hormonal theory is linked to extraovarian production of estrone. Adipocytes can convert androstenedione to estrone. Estrone stimulates CSF production, and, in patients with limited absorptive capacity, this can lead to increased ICP. In women, a combination of the two possibilities is likely, explaining the higher prevalence of the condition observed in women. The therapeutic implications are important, because weight loss, whether via dieting or surgical intervention, has been shown to lead to resolution of papilledema.
Clinical Findings
The symptoms of IIH can be divided in two groups: classical-or major-and minor. Classically, it has been accepted that headache, nausea, transient visual obscurations (TVOs), permanent afferent visual pathway damage, intracranial bruit, and diplopia from abducens palsy are compatible with the diagnosis of IIH, and these are considered the majoror classical-symptoms. A variety of other symptoms also have been reported in IIH, however, including neck stiffness, tinnitus, distal appendicular paresthesias, shoulder and arm pain, joint pains, low back pain, ataxia, retrobulbar pain on eye movement, decreased sense of smell, fatigue, weakness, and dyscoordination (Table 3) . Worsening of any symptoms with postural changes such as bending over or by performing a Valsalva maneuver are characteristic of IIH. The predominant symptom differs depending on the age group. Children usually present with increased irritability or diplopia, whereas adults report headache and TVOs.
Headaches are present in about 95% of patients with IIH. The headache usually is most pronounced in the morning, and it usually is retro-ocular and pulsatile. It may awaken the patient and last for hours. It typically is reported to be different from and much worse than previous headaches that the patient might have experienced. Eye movements may exacerbate IIH-related headache. Preexistent migraine may be worsened by IIH. Surprisingly, there is no clear correlation between the height of the CSF pressure and the severity of the headaches. Nausea is a relatively common symptom, but vomiting is much less frequent, occurring in about 20% of patients with severe IIH. Neck stiffness occurs in 30% to 50% of patients.
Acral paresthesia unrelated to medication intake is reported in 25% of patients with IIH. The symptom is described as episodic tingling and painful sensation in all extremities without any objective sensory findings, and it can be associated with headaches.
Arthralgia is reported in 11% to 18% of IIH patients, described as dull, aching pain in the shoulders, wrists, and knees. The cause-effect relationship is confirmed by their resolution with CSF drainage.
"Ataxia" occurs in 4% to 11% of patients, and it typically begins on rapid postural change or locomotion. Lack of coordination has been reported in up to 18% of patients.
Pulse-synchronous tinnitus occurs in up to 60% of patients with IIH. It may be unilateral or bilateral. Patients classically describe the symptom as a rushing sound noticed in the silence of the night before sleep. In unilateral cases, it may be eliminated by ipsilateral jugular compression and ipsilateral head turning. Normalization of ICP with lumbar puncture (LP), Diamox (acetazolamide; Wyeth, Madison, NJ), or shunting eliminates the tinnitus.
Patients may experience TVOs. Graying or blacking out of vision occurs for about a second in at least 90% of IIH patients. The severity of papilledema is directly proportional to the incidence of this symptom. The TVOs can be unilateral or bilateral, sequential, or simultaneous if bilateral. They typically occur with eye movement, bending over, or performing a Valsalva maneuver. The frequency of TVOs correlates with the level of ICP elevation but is not predictive of permanent visual loss.
Cranial Nerve VI is compressed intracranially due to elevated ICP; the petrous ridge has been suggested as the site of injury. Involvement of the abducens nerve typically is unilateral but can be bilateral. Patients may report horizontal binocular diplopia that is worst at distance. On examination, limitation of abduction and esotropia are present. In mild cases of abducens palsy, the esotropia may be noticed on extreme lateral gaze only. This palsy resolves with normalization of intracranial hypertension.
Psychological Profile and Cognitive Dysfunction. Traditionally, the management goals for IIH include preventing permanent visual loss and providing relief from the headache. However, psychological and cognitive aspects of the disease are commonly overlooked. Patients with IIH have impaired quality of life. Depression, anxiety, and chronic fatigue are reported more frequently in patients with IIH than in age-, gender-, and weight-matched individuals. These findings may be attributable to the disease itself, a reaction to the disease, the complexity and difficulty of treatment, the medications used to treat the disease, or a combination of these factors. Up to 25% of patients with IIH have persistent chronic cognitive dysfunction on neuropsychological testing. The dysfunction is improved with intensive medical treatment or shunting, which points to increased ICP as the culprit.
Idiopathic Intracranial Hypertension Without Papilledema
Idiopathic intracranial hypertension without papilledema (IIHWOP) represents a special subset of IIH. The concept was introduced in the neurological literature during the past three decades to explain how some patients with IIH do not have papilledema. The criteria employed for the diagnosis of IIHWOP include the presence of symptoms of IIH, CSF pressure greater than 200 mm H 2 O on two sequential measurements, absence of papilledema, and a normal neurological evaluation. Visual loss does not tend to be reported in this group, but relief of headaches can be challenging. There have been reports of obese patients with chronic headache in whom pulse-synchronous tinnitus may be a significant predictor of IIHWOP. The treatment for IIHWOP is symptomatic, and prophylactic headache therapy is useful. Repeat LPs occasionally are helpful but are fraught with the risk of low-pressure headache due to persistent CSF leak. Cerebrospinal fluid shunting procedures should be used as the treatment of last resort in patients who are incapacitated by their symptoms despite aggressive medical therapy, and who respond consistently to LPs.
Diagnosis

Determining Intracranial Pressure via Lumbar Puncture
Documentation of increased ICP is considered indispensable for the diagnosis of IIH. Increased ICP usually is determined by measuring the opening pressure on an LP in the lateral decubitus position. The physician needs to consider the following factors, however, when interpreting CSF pressure values. First, variability in daily ICP fluctuation must be kept in mind, because ICP fluctuates widely during the day in the normal population. These fluctuations are even more pronounced in the IIH population; 24-hour monitoring of ICP has demonstrated normal ICP values at times in patients with fullblown IIH. Dandy noted this phenomenon in his original paper on IIH-he observed fluctuations in the degree of fullness of the decompressive flap used to treat his patients with IIH. If the clinical suspicion is high, and the opening pressure is normal on first attempt, a repeat LP at a different time of the day may be necessary. Another variable is the patient's weight. In determining the upper limit of normal ICP values, it was found that higher pressures are observed in otherwise asymptomatic obese patients compared to patients with normal weight. Opening pressures recorded in the sitting or prone position may be artificially elevated. Pain or anxiety during the procedure also may raise the pressure.
Neuro-Ophthalmic Examination
All patients with suspected increased ICP should be evaluated by a neuro-ophthalmologist. Accurate testing of visual acuity, color vision, contrast sensitivity, pupillary function, motility, visual fields, and the ocular fundus are crucial. Bilateral disc edema is a characteristic feature of increased ICP (Fig. 1) . The pathological changes may range from subtle nerve fiber layer elevation to absence of spontaneous venous pulsations, loss of the optic cup, and obscuration of the optic nerve vessel. A hasty examiner who may be expecting massive elevation of the optic nerve with associated venous tortuosity, exudates, and hemorrhages may easily miss these changes. Visual acuity is a relatively insensitive measure of visual function in papilledema. Much more sensitive are color vision, contrast sensitivity, and careful visual field testing. The increased ICP is transmitted along the optic nerve sheath, resulting in circumferential compression of the retinal ganglion cell axons at the level of the lamina cribrosa. Early damage of the afferent visual pathways may be detectable only in the peripheral visual fields as well as in the nasal quadrant (Fig. 2) . Confrontational visual field testing is a particularly insensitive method of ascertaining field loss in IIH. Damage often is symmetric, so a relative afferent pupillary defect may be absent. Unilateral or bilateral abducens palsy may be present. The esotropia may range from a small (< 5 prism diopters) to a large (> 50 prism diopters) disconjugate angle in primary gaze. The remainder of the neuroophthalmic examination characteristically is normal. Figure 1 . Photograph of a fundus demonstrates severe ischemia due to sudden shunt failure in a patient with idiopathic intracranial hypertension. The papilledema is accompanied by exudates, hemorrhages, and venous dilation and tortuosity.
Laboratory Evaluation
Cerebrospinal Fluid Analysis. The composition of the CSF is normal by definition; analysis, however, is helpful in ruling out possible secondary etiologies or associated conditions. Routine tests are performed for glucose, protein, cell count, and aerobic bacterial culture. A tube of CSF should be retained to perform additional tests if the standard profile is abnormal. Additional studies may be required to rule out infection (e.g., fungus, tuberculosis, or Lyme disease); inflammation (e.g., sarcoidosis or systemic lupus erythematosus); or neoplasia (e.g., lymphomatous or carcinomatous meningitis).
Other Laboratory Evaluation. No additional laboratory evaluation is indicated in typical patients with characteristic symptoms and a normal CSF profile. If the CSF profile is abnormal, however, a more extensive work-up is indicated to look at possible causes of IIH.
Neurodiagnostic Imaging Studies
Imaging of the brain is indicated to rule out any intracranial mass lesion that may be causing papilledema. The study of choice in the workup of IIH is MRI, because subtle radiological signs of intracranial hypertension may be detected better with this modality than with CT. These signs include flattening of the posterior sclera, which occurs in 80% of patients with IIH; empty sella, seen in 30% to 70% of patients with IIH; enhancement of the prelaminar optic nerve, seen in 50% of patients with IIH; distention of the perioptic subarachnoid space, which is seen in 45% of patients; vertical tortuosity of the orbital optic nerve, seen in 40% of patients; and intraocular protrusion of the prelaminar optic nerve, apparent in 30% of patients (Fig. 3) . Various studies have failed to show definite evidence of smaller ventricular size in patients with IIH compared with normal controls. An MR venogram is useful to rule out venous obstruction. Rarely, a conventional venogram may be necessary.
If the protein is abnormal, MR imaging of the spine should be performed, when the clinical setting is appropriate.
Differential Diagnosis Adult Chiari Malformation
Adult Chiari malformation (ACM) has been associated with IIH. In fact, 2% to 5 % of patients with ACM are reported to have papilledema, and 6% of patients with IIH have significant tonsillar ectopia. The ball-valve effect produced by the ectopic tonsils may lead to intracranial hypertension. Currently there is controversy as to whether treatment of papilledema in patients with IIH should include surgical decompression of the ACM. Suboccipital decompression usually is reserved for patients who do not respond to medical treatment and is preferred to shunting procedures because it may lead to permanent cure rather than shunt dependency. In cases that come to surgery, particular attention should be paid to closure to avoid a CSF leak. 
Pseudopapilledma and Other Optic Neuropathies
Papilledema commonly is misdiagnosed in patients with migraine or tension headaches and "full" optic nerves. The optic nerve head is best evaluated using a slit lamp and high magnification, such as that available with 60-or 78-diopter hand-held lenses. Pseudopapilledema is diagnosed in patients with crowded and full-appearing optic discs that otherwise contain optic nerve head drusen, are hyperopic, or are congenitally engorged. Although the optic nerve appears elevated, in patients with pseudopapilledema there is no nerve fiber layer disturbance obscuring visualization of the retinal vessels, exudates, or hemorrhages. In congenitally anomalous nerves, the vessels often appear more tortuous than usual. Spontaneous venous pulsations usually are present. Ancillary testing to confirm the present of optic nerve drusen includes B-mode ultrasound and orbital CT scanning. No interventions are necessary for pseudopapilledema. Reassurance and proper headache management are the most effective treatment.
Bilateral disc edema can occur in malignant hypertension, and the appearance of the optic nerve head often is indistinguishable from true papilledema. The blood pressure should be measured in all patients with optic nerve head elevation in case the cause is malignant hypertension. Bilateral disc edema also can occur in patients with bilateral vein occlusions or closely sequential ischemic optic neuropathies. Once again, careful evaluation by a neuro-ophthalmologist will provide the correct diagnosis and recommendations for management.
Treatment Options
Natural History
Idiopathic intracranial hypertension is described as a selflimited disease with spontaneous resolution. Resolution occurs at variable intervals, sometimes within months, but more commonly after more than a year. Generally IIH has a good long-term outcome, but this depends on the criteria used to define "good" outcome: resolution of papilledema, preservation of vision, resolution of the other symptoms of IIH, or resolution of the hydrodynamic alterations of IIH. Although papilledema resolves in most cases, it may persist in as many as 15% of patients, and permanent visual loss occurs in 2% to 24% of affected individuals. A significant percentage of patients also experience other persistent alterations, such as persistent headache, persistent cognitive dysfunction, and hydrodynamic alterations in the form of increased ICP and decreased CSF conductance. Recurrence is seen in about 10% of cases after apparent initial resolution.
Nonoperative Approaches
Diet. Diet and weight loss have been proven to reduce papilledema. Aweight loss of 6% was found to lead to complete resolution of papilledema. Various diets have been proposed.
Carbonic Anhydrase Inhibitors. Acetazolamide, the first-line therapy, is a carbonic anhydrase inhibitor that reduces CSF production. A minimum dose of 500 mg twice daily results in significant and sustained reduction of ICP elevation. The maximum recommended dose is 1500 mg twice daily. Acetazolamide may be taken as a 250-mg tablet or a 500-mg capsule. The capsule is preferred due to its sustained release. Side effects include fatigue, tingling of extrem-ities, and alteration of taste (especially of carbonated drinks). Acetazolamide is contraindicated in patients with an allergy to sulfa or a history of kidney stones.
Unusual complications include hyperchloremic acidosis, bone marrow depression, Stevens-Johnson syndrome, agranulocytosis, blood cell dyscrasia, and toxic epidermal necrolysis. A baseline complete blood count with differential and electrolyte panel should be obtained before beginning treatment with acetazolamide. The primary care doctor should be notified if the patient is on antihypertensive or potassium-depleting medication.
Methazolamide (Neptazane; Wyeth) is another carbonic anhydrase inhibitor. It is better tolerated but less effective and is given in a range of 50 to 100 mg, two to three times per day. Its sideeffect and therapeutic profile is similar to that of acetazolamide.
Topiramate is an anticonvulsant that has a secondary effect as a carbonic anhydrase inhibitor. It also has analgesic properties. Side effects are similar to those of acetazolamide and include somnolence, fatigue, kidney stones, and paraesthesias. Doses must be adjusted in renal or hepatic disease. Topiramate can be used in patients with an allergy to sulfa medications. Clinical studies regarding its effectiveness in IIH are lacking. The recommended dose is 200 mg twice daily. It is also available in 15-mg or 25-mg sprinkle capsules for children.
Other Diuretics. Furosemide has been used in patients who cannot tolerate acetazolamide or in combination with acetazolamide. Its effectiveness is not well documented. The minimum initial dose is 20 mg twice daily. Potassium levels should be monitored. It also is contraindicated in patients with sulfa allergies and can result in dehydration and potassium depletion. Ethacrynic acid has been tried in sulfa-allergic individuals with anecdotal success.
Corticosteroids. Corticosteroids may increase CSF outflow in patients with a history of trauma, inflammation, or venous thrombosis. They are useful as a temporizing agent in patients with severe visual impairment who are awaiting emergency surgical decompression. Methylprednisolone, 250 mg IV every 6 hours, can improve visual function and headache rapidly and may reduce papilledema over time. Long-term oral corticosteroid therapy is not recommended, because it may result in weight gain that exacerbates the primary disease process in IIH.
Headache Management. In patients with normal visual function and minimal elevation of the ICP, medical management of the headache with aspirin, nonsteroidal anti-inflammatory drugs, and anti-migraine therapy is preferable. Amitriptyline may be started at a low dose and titrated upward until it reaches an effective level. The dosage is 25 to 100 mg taken 2 hours before bedtime. Anticholinergic side effects and somnolence are limiting.
Serial Lumbar Punctures. Serial LPs have been reported to be successful as the sole treatment modality in about 40% of patients. The mechanism of action consists of creation of a dural puncture site that will promote leakage within the epidural space for a variable period. Disadvantages include procedural discomfort, low-pressure headache, and the potential for infection. The role of repeated LPs in acquired cerebellar tonsillar descent is yet to be defined. Given the availability of other superior and less painful treatments, serial LPs are no longer routinely recommended and are actively discouraged by some authors unless the patient is not a candidate for any other therapeutic modality.
Operative Approaches
Optic nerve sheath fenestration (ONSF) is indicated in some patients with impending permanent visual dysfunction despite maximal medical therapy. There is good evidence from several reports that patients whose primary symptom is intractable headache rather than visual loss attributable to IIH may experience greater improvement from a shunting procedure than from ONSF. Morbid obesity may be treated bariatrically with a gastric bypass procedure.
Optic Nerve Sheath Fenestration. Optic nerve sheath fenestration is performed from a medial, or, less commonly, a lateral orbitotomy approach. The medial approach involves medial rectus disinsertion from the globe to allow identification and fenestration of the optic nerve sheath. Multiple slits or windows are created with care to avoid the vessels covering the optic nerve sheath. Agush of fluid is visible with each successful slit. The medial rectus is reattached and an eye patch applied. In experienced hands, the procedure is very successful. Visual field is improved in 55% to 100% of eyes. Repeat fenestration is required in only 0% to 6% of eyes. Risks include direct injury to the nerve, hemorrhage, ischemic optic neuropathy, and venous or arterial occlusion. Temporary double vision from medial rectus disinsertion is not uncommon. Long-term studies have reported nearly universal resolution of papilledema following ONSF; however, the procedure is not as effective at treating other symptoms of increased ICP, such as headaches. Occasionally a patient may require both ONSF and shunting to relieve intractable papilledema and massive headaches.
Neurosurgical Procedures. The neurosurgical armamentarium in the treatment of IIH includes cranial decompressions and shunting. Surgery is reserved for select cases that resist maximal aggressive medical management.
Cranial decompression. Decompression can be subtemporal or suboccipital. It initially was advocated by Davidoff and Dyke and by Dandy; however, interest in this procedure has waned over the past decades as the use of ONSF and shunting procedures has become more widespread.
Lumboperitoneal shunting. Most neurosurgeons prefer lumboperitoneal shunting (LPS) to ventriculoperitoneal shunting (VPS) because small to normal-size ventricles make ventricular catheter placement technically difficult. This concern has been lessened by the widespread availability of stereotactic ventricular catheter insertion techniques. Either shunt, when functional, is highly successful in managing the symptomatic patient with IIH. The failure rate is elevated, however, with roughly 50% of shunts requiring revision. Some problems are encountered that are specific to LPS, such as sciatica from lumbar nerve root irritation, acquired tonsillar ectopia, and low-pressure headache resulting from intracranial hypotension. The associated obesity in patients with IIH adds to the challenge in placing these shunts.
Ventricular shunting. Ventricular shunting is used less frequently because of the lack of ventriculomegaly. Recent advances in stereotactic techniques, however, especially frameless stereotaxy, make it a viable option. We have used the latter technique in more than ten patients with accurate placement.
Bariatric Surgery. Bariatric surgery, in the form of gastric bypass and even laparoscopic banding, has been used in obese patients with IIH with good results. Most symptoms related to IIH eventually resolve with bariatric intervention. Symptomatic recurrence is associated with weight gain. Bariatric surgery also offers the advantage of preventing other deleterious long-term consequences of morbid obesity.
Idiopathic Intracranial Hypertension And Pregnancy
Idiopathic intracranial hypertension is relatively common in obese women of childbearing age. Some women first present with IIH during pregnancy, whereas others have exacerbation of an established diagnosis of IIH during pregnancy. Full resolution of IIH following delivery is not uncommon in the former group of women, but women with IIH who become pregnant during established treatment are more challenging to treat. The goal is to keep the mother comfortable and prevent visual loss while minimizing potential toxicity to the growing child. In the first trimester, observation, limitation of weight gain, and serial LPs are preferred. In the second and third trimesters, acetazolamide has been used safely in scores of patients. Use of this drug in pregnant women remains controversial, however, because animal studies demonstrate teratogenicity (although at acetazolamide doses well above those currently used in human treatment). The involvement of an obstetrician experienced or specializing in high-risk pregnancies is recommended.
Idiopathic Intracranial Hypertension in Adolescents and Children
Secondary intracranial hypertension has been reported in children following steroid taper for asthma. Idiopathic intracranial hypertension has been described in adolescents using the cycline antibiotics (tetracycline and doxycycline) or Accutane (Roche, Nutley, NJ). Endocrinopathy, hypervitaminosis A, electrolyte imbalance, malnutrition, hypercalcemia, and cancer are known associations. Acetazolamide has been used successfully in children and adolescents. A search for a cause is essential, because removal of the offending agent is curative.
Recommended Therapy
Treatment must be tailored to patients individually. Because patients' concerns vary from visual loss to headaches to the various other symptoms, treatment should be geared to the symptoms that are having a significant affect on the specific patient, starting with the least and moving toward the most invasive therapy.
Headache Without Visual Loss
Over-the-counter headache medications may be used for relief of mild or moderate headache. For headaches that cannot be controlled with these medications or severe headache with ICP greater than 300 mm H 2 O, Diamox, 500 mg twice daily, or serial LPs may be necessary. Gastric bypass may be indicated if the patient is morbidly obese.
Visual Loss without Headache
Visual field testing is key in determining treatment of visual loss without headache. Mild visual field loss may be treated with Diamox 500 mg twice daily. This dosage may be increased to 1500 mg twice daily if necessary. Weight loss should be encouraged. Initially, the patient should be followed up every 2 weeks.
For moderate visual loss, Diamox 1000 mg twice daily is prescribed. The dosage may be increased to 1500 mg twice daily if necessary. The patient is encouraged to lose weight, and is followed-up weekly at first.
Severe visual loss, moderate visual loss that does not respond to Diamox, or disc at risk is treated with intravenous methylprednisolone, 250 mg every 6 hours, and Diamox 1000 mg twice daily. If there is no visual improvement, optic nerve sheath fenestration is performed. A gastric bypass may be done in morbidly obese patients. Shunting is considered if the ICP is higher than 300 mm H 2 O.
Summary
Idiopathic intracranial hypertension is a relatively common disease in obese women of childbearing age. Neuroimaging and LP are diagnostic. Extensive laboratory and imaging evaluations should be performed in children, non-obese patients, and men. Management goals include control of the headache and prevention of permanent visual loss. The effect of the disease process on the patient's quality of life also should be considered. Management options should be tailored to the patient's needs and include observation, weight loss, oral and intravenous therapeutics, and surgical intervention.
